'We Must Innovate': US Biotechs Chart New Growth Path In China
Transparency, Predictability Still Thorny, BIO Hears
Facing a increasingly competitive environment and tense bilateral relationship, US biotechs must innovate and differentiate while protecting their innovations in China, say panelists at the BIO annual conference.
You may also be interested in...
Early study results show CanSino’s inhaled vaccine for COVID-19 triggered an immune response similar to its injected counterpart.
The US listing of Chinese artificial intelligence, medical records and patient management system company Linkdoc could be derailed, after China issued new data review requirements tightening the oversight of overseas listings of domestic companies.
Sales of the Swiss drug maker's major plaque psoriasis treatment Cosentyx in China quadrupled in the second quarter, despite its price being slashed by more than 60%.